Trial Profile
a pilot trial of daily oral ZD1839 (Iressa) [gefitinib] with standard doses of carboplatin and paclitaxel in patients with advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Feb 2010
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 17 Dec 2009 Actual end date (Mar 2002) added as reported by ClinicalTrials.gov.
- 04 Sep 2005 New trial record.